Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Recent updates in MCL

Georg Hess • 8 Jun 2021
EHA 2021
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Lenalidomide Venetoclax

Georg Hess, MD, University Medical Center Mainz, Mainz, Germany, comments on recent updates in the treatment of patients with mantle cell lymphoma (MCL), highlighting the use of novel combinations such as venetoclax plus lenalidomide and a novel scoring system. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Georg Hess

1:46
Emerging options for patients with MCL who relapse after a frontline BTKi
Georg Hess • 20 Oct 2023
1:44
Indirect comparison of brexu-cel versus SOC in R/R MCL
Georg Hess • 20 Oct 2023
2:37
The changing role of autoSCT in mantle cell lymphoma: the impact of novel agents
Georg Hess • 20 Oct 2023
2:31
Optimizing treatment of MCL
Georg Hess • 8 Jun 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals